This Analyst Sees Potential Downside In Eli Lilly, Adjusts Model For Acquired IPR&D Charges

Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating on the shares of Eli Lilly And Co (NYSE:LLY) and maintained a price target of $885.The company is slated to report its second-

BenzingaJul 15 13:13 ET

Akero Therapeutics(AKRO.US) Officer Sells US$117.02K in Common Stock

$Akero Therapeutics(AKRO.US)$ Officer Young Jonathan sold 5,000 shares of common stock on Jul 1, 2024 at an average price of $23.404 for a total value of $117.02K.Source: Announcement What is statemen

Moomoo NewsJul 2 19:38 ET

Form 144 | Akero Therapeutics(AKRO.US) Officer Proposes to Sell 351.9K in Common Stocks

SEC FILLINGS DISCLOSED/ Jul 1, $Akero Therapeutics(AKRO.US)$ Officer Jonathan Young intends to sell 15,000 shares of its common stock on Jul 1, with a total market value of approximately $351.9K. Jo

Moomoo NewsJul 1 16:10 ET

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Akero Therapeutics

Faruqi & Faruqi Logo (PRNewsfoto/Faruqi & Faruqi, LLP)

PR NewswireJun 13 11:25 ET

Express News | Cantor Fitzgerald Reiterates Overweight on Akero Therapeutics

BenzingaJun 12 12:09 ET

CCORF Maintains Akero Therapeutics(AKRO.US) With Buy Rating, Maintains Target Price $56

CCORF analyst Edward Nash maintains $Akero Therapeutics(AKRO.US)$ with a buy rating, and maintains the target price at $56.According to TipRanks data, the analyst has a success rate of 40.9% and a tot

moomoo NewsJun 12 08:33 ET · Ratings